| Status | Select a city |
| Brand | World Medicine / World Medicine |
| Brand country | |
| Quantity and shape | 1 vial |
| Generics | phenyleprine+dexamethasone+neomycin+polymixin B sulfate |
| Volume | 15მლ |
Rinetra
Name of the medicinal product
Rinetra, Rinetra
International Nonproprietary Name or Group Name
Neomycin + Polymyxin B + Dexamethasone + Phenylephrine
Neomycin + Polymyxin В + Dexamethasone + Phenylephrine
1 ml of the preparation contains
Active substance: neomycin sulfate 6500 IU, polymyxin B sulfate 10000 IU, dexamethasone sodium metasulfobenzoate 0.25 mg, phenylephrine hydrochloride 2.5 mg.
Excipients: methyl parahydroxybenzoate, sodium chloride, citric acid monohydrate, macrogol 4000, polysorbate 80, sodium hydroxide, purified water.
Dosage form
Nasal spray.
Description: clear, colorless or slightly yellowish solution.
Inflammatory and infectious diseases of the nasal cavity, pharynx, paranasal sinuses:
- acute and chronic rhinitis;
- Acute and chronic rhinopharyngitis;
- Sinusitis.
Dosage
Adults: one spray in each nostril 3-5 times a day.
For children from 2.5 to 18 years of age: one spray in each nostril 3 times a day.
The duration of treatment is 5-10 days.
Rinetra spray is intended for intranasal use only.
When using the bottle should be held vertically with the nozzle pointing upwards.
- Hypersensitivity to the active substances of the drug or any excipient;
- Suspected closed-angle glaucoma;
- Simultaneous use of monoamine oxidase (MAO) inhibitors;
- Viral diseases;
- Kidney diseases accompanied by albuminuria;
- Renal failure;
- Pregnancy;
- Lactation;
- Children under 2.5 years of age.
Rinetra is contraindicated during pregnancy and lactation.
Effect on the ability to drive vehicles and operate machinery
Data on the negative effect of the drug on the ability to drive vehicles and operate machinery does not exist.
Overdose
Due to the low degree of absorption into the systemic blood circulation, overdose is unlikely.
Pharmacodynamic properties
Pharmacotherapeutic group: Decongestants and other nasal preparations for topical use. Dexamethasone in combination. ATC code: R01AD53
Rinetra is a combined preparation for local use in otorhinolaryngology. It has the anti-inflammatory effect of dexamethasone on the nasal mucosa and the antibacterial effect of neomycin and polymyxin B.
Dexamethasone is well absorbed during local use and its absorption increases during inflammation of the mucous membrane. In the specified combination of antibiotics, the spectrum of antibacterial activity is broadened against most gram-positive and gram-negative microorganisms that cause infectious and inflammatory diseases of the nasal cavity and paranasal sinuses.
Pharmacokinetic properties
No data available.
Shelf life
3 years from the date of production.
Do not use after the expiry date.
Store at a temperature not exceeding 25°C.
Keep out of the reach of children!
Type and contents of packaging
15 ml nasal spray in a white plastic bottle with a dosing device and a protective cap or 15 ml in a yellow glass bottle with a dosing device and a protective cap.
1 bottle together with the instruction for medical use in a cardboard box.
Also, see: Neladex - Neladex Ns Ns Nasal Spray 15ml
Translated by AI